Merck says cyber attack halted production, will hurt profits
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Merck to Collaborate with Generex to Evaluate KEYTRUDA (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast Cancer
July 31, 2017 9:41 AM EDTMerck (NYSE: MRK) (known as MSD outside the United States and Canada), through a wholly-owned subsidiary today announced that through a collaboration agreement with Generex Biotechnology Corporation and its wholly-owned subsidiary, Antigen Express, Inc has entered into a clinical trial to evaluate Antigens AE37 cancer vaccine in combination with Mercks anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic triple-negative breast cancer. The study will evaluate preliminary safety and efficacy of the combination in a Phase II trial.
The combination of AE37 plus KEYTRUDA follows previous studies, in which both... More
